Xencor Beat Consensus Estimates
Wednesday, August 6, 2025 at 4:01 PM ET
Xencor (XNCR) reported a loss of $0.41 per share on revenue of $43.61 million for the second quarter ended June 2025. The consensus estimate was a loss of $0.78 per share on revenue of $20.10 million. The company beat consensus estimates by 47.44% while revenue grew 157.12% on a year-over-year basis.
Xencor Inc is a clinical-stage biopharmaceutical company. It is engaged in discovering and developing engineered monoclonal antibodies to treat severe and life-threatening diseases with unmet medical needs.
Earnings Whisper Grade
Power Rating
Reported Earnings
$-0.41
Earnings Whisper®
-
Consensus Estimate
$-0.78
Earnings Surprise
Earnings Growth
Reported Revenue
$43.61 Mil
Revenue Estimate
$20.10 Mil
Revenue Surprise
Revenue Growth